MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$4,592K
EPS
-$0.12
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
1,055
413
1,376
634
Selling, general and administrative
3,457
2,435
4,219
2,748
Loss from operations
-4,512
-2,848
-5,595
-3,382
Interest income
58
67
17
36
Interest expense
64
63
32*
-
Loss on initial recognition of greenshoe rights liability
-
-
20,209*
-
Change in fair value of greenshoe rights liability
-
-
-2,853*
-
Change in fair value of warrant liability
-
-11
3
-232
Gain on settlement of vendor payable
-
-
250*
-
Other
-
-
-312*
-
Total other income (expense), net
-6
15
-17,436
268
Net loss
-4,518
-2,833
-23,031
-3,114
Dividend on series l preferred stock
-
-
-80*
-
Dividend on preferred stock
74
103
-
-
Deemed dividend
-
433
-5,786*
144
Net loss attributable to common stockholders
-4,592
-3,369
-28,897
-3,258
Basic EPS
-0.12
-0.11
-5.241
-0.83
Diluted EPS
-0.12
-0.11
-5.241
-0.83
Basic Average Shares
38,820,657
30,283,031
5,513,255*
3,940,714
Diluted Average Shares
38,820,657
30,283,031
5,513,255*
3,940,714
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
attributable to common...
-$4,592K
(-202.50%↓ Y/Y)
Net loss
-$4,518K
(-215.28%↓ Y/Y)
Dividend on preferred
stock
$74K
Loss from operations
-$4,512K
(-198.22%↓ Y/Y)
Total other income
(expense), net
-$6K
(-107.50%↓ Y/Y)
Interest income
$58K
(52.63%↑ Y/Y)
Selling, general and
administrative
$3,457K
(200.61%↑ Y/Y)
Research and development
$1,055K
(190.63%↑ Y/Y)
Interest expense
$64K
Buy us a coffee
GT Biopharma, Inc. (GTBP)
GT Biopharma, Inc. (GTBP)